Avantor Lifts 2026 Organic Growth Outlook, Now Sees Up to +0.5%
AVTR sits 78% above its 52-week low of $7.265 on elevated volume (2.0× avg).
Summary
Avantor raised its 2026 organic revenue growth guidance to a range of -0.5% to +0.5%, up from the prior -2.5% to -0.5%, and also raised its 2026 adjusted EPS outlook to $0.80-$0.83. The midpoint improvement of 100 basis points signals a meaningful recovery in demand trends, likely driven by improving end-market conditions in biopharma and research. This follows a challenging Q1 where net income and cash flow declined sharply, and the company warned of goodwill impairment risk. The guidance lift suggests stabilization and potential return to growth, which could ease concerns about further write-downs. The refinancing of euro term loans in mid-July at lower rates also supports margin improvement. With a market cap near $8.5 billion, the revised outlook is a material positive signal for the second half, and Q2 results beat expectations.
At the time of this announcement, AVTR was trading at $12.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.5B. The 52-week trading range was $7.27 to $15.93. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.